Invasive Kardiologie

Publikationen

2009

• Jeger RV, Schneiter S, Kaiser C, Bonetti PO, Brunner-La Rocca H, HandkeM, Osswald S, Buser PT, Pfisterer ME, for the BASKET Investigators
  Drug-Eluting Stents Compared with Bare Metal Stents Improve Late Outcomeafter Saphenous Vein Graft but Not after Large Native Vessel Interventions
  Cardiology 2009;112:49–55. Impactfactor 1.70
• Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, Hunziker P, Mueller C, Nietlispach F, Leibundgut G, Bader F and Kaiser C for the BASKET Investigators
  Long-term benefit–risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET
  Eur Heart J 2009; 30:16-24. Impact Factor 7.92
• Kaiser C, Pfisterer M
  Erhöhtes Risiko für Stentthrombosen bei DES?
  Herz 2007;23:296-300

2008

• Pfisterer M, Brunner-La Rocca HP, Kaiser C
  The balance of risks and benefits of drug-eluting versus bare-metal stents
  JACC 2008;51:972
• Maeder MT, Pfisterer ME, Buser PT, Roser HW, Roth J, Weilenmann D, Nietlispach FP, Zellweger MJ, Amsler B, Kaiser CA
  Long-Term Outcomes after Intracoronary b-irradiation for In-Stent Restenosis in Bare-Metal Stents
  J Invasive Cardiol 2008;20:179–184
• Pfisterer M, Bertel O, Bonetti PO, MD, Brunner-La Rocca HP, Eberli FR, Erne P, Galatius S, Hornig B, Kiowski W, Pachinger O, Pedrazzini G, Rickli H, De Servi S, Kaiser C, for the BASKET-PROVE Investigators
  Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE(PROspective Validation Examination) trial: Study protocol and design
  Am Heart J 2008;155:609-14. Impact Factor: 3.65
• Maeder MT, Stauffer JC,Windecker S, Pedrazzini G, Kaiser CA, Roffi M, Rickli H; on behalf of the Working Group “Interventional Cardiology and Acute Coronary Syndrome”
  Interventional cardiology in Switzerland 2006
  Kardiovaskuläre Medizin 2008;11:187–195
• De Luca G, Stone GW, Suryapranata H, Laarman GJ, Menichelli M, Kaiser C, Valgimigli M, Di Lorenzo E, Dirksen MT, Spaulding C, Pittl U, Violini R, Percoco G, Marino P
  Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials
  Int J Cardiol 2008 Apr 2. [Epub ahead of print]
• Jeger RV, Radovanovic D, Hunziker PR, Pfisterer ME, Stauffer JC, Erne P, Urban P, for the AMIS Plus Registry Investigators
  Ten-Year Trends in Incidence and Treatment of Cardiogenic Shock
  Ann Intern Med 2008;149(9):618-26. Impact factor 15.5, ranking 4/100 (Medicine, General & Internal) 2007
• Jeger RV, Rickenbacher P, Pfisterer ME, Hoffmann A
  Outpatient cardiac rehabilitation in patients with peripheral arterial occlusive disease
  Arch Phys Med Rehabil 2008;89:618-21. Impact factor 1.8

2007

• Brunner-La Rocca HP, Kaiser C, Pfisterer M on behalf of the BASKET Investigators
  Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET)
  Eur Heart J 2007; 28:719-25
• Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbæk H, Menichelli M, Sabaté M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig M
  Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
  N Engl J Med 2007 356;10: 1030-39
• Brunner-La Rocca HP,* Kaiser C,* Bernheim A, Zellweger MJ, Jeger R, Buser PT, Osswald S, Pfisterer M, for the BASKET Investigators. *: contributed equally
  Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent Kosten Effektivitäts Trial (BASKET): an 18-month analysis
  Lancet 2007; 370: 1552–59. Impact Factor: 28.64
• Kastrati A, Dibra A, Spaulding C, aarman GJ, Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, MehilliJ, Seyfarth M, Varenne O, Dirksen MT, PercocoG, Varricchio A, Pittl U, Syvänne M, Suttorp MJ, Violini R, Schömig A
  Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction
  Eur Heart J 2007;28: 2706–13
• Schömig A, Dibra A, Windecker S, Mehili J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Jüni P, Pfisterer M, Meier B, Kastrati A
  A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease
  J Am Coll Card 2007;50:1373-80
• Farkouh ME, Greenberg JD, Jeger RV, Harrington RA, Ramanathan K, Verheugt FW, Kirshner H, Chesebro JH, Hochman JS, Lay CL, Ruland S, Mellein B, Matchaba PT, Fuster V, Abramson SB, on behalf of the TARGET Study Group
  Cardiovascular outcomes in high-risk patients with osteoarthritis treated with ibuprofen, naproxen, or lumiracoxib: a post-hoc analysis of the TARGET Trial
  Ann Rheum Dis 2007; 66:764-70. Impact factor 6.4, ranking 2/21 (Rheumatology) 2007
• Jeger RV, Assmann SF, Yehudai L, Ramanathan K, Farkouh ME, Hochman JS, for the SHOCK Investigators
  Causes of death and re-hospitalization in cardiogenic shock
  Acute Cardiac Care 2007;9:25-33
• Jeger RV, Lowe AM, Buller CE, Pfisterer ME, Dzavik V, Webb JG, LeJemtel TH, Hochman JS, Jorde UP, for the SHOCK Investigators
  Hemodynamic parameters are prognostically important in cardiogenic shock but similar following early revascularization or initial medical stabilization - A report from the SHOCK Trial
  Chest 2007;132:1794-803. Impact factor 4.1, ranking 6/34 (Respiratory System) 2007
• Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A
  Patent foramen ovale and cryptogenic stroke in older patients
  N Engl J Med. 2007 Nov 29;357(22):2262-8
• Jeger RV, Seeberger MD, Keller U, Pfisterer ME, Filipovic M
  Oral hypoglycemics: increased postoperative mortality in coronary risk patients
  Cardiology 2007;107:296-301 Impact factor 1.7
• Jeger RV, Jörg L, Rickenbacher P, Pfisterer ME, Hoffmann A
  Benefit of outpatient cardiac rehabilitation in under-represented patient subgroups
  J Rehabil Med 2007;39:246-51 Impact factor 2.0

Älter als 2007

• Zellweger MJ, Lewin HC, Lai S, Dubois EA, Friedman JD, Germano G, Kang X, Sharir T, Berman DS
  When to stress patients after coronary artery bypass surgery? Risk stratification in patients early and late post-CABG using stress myocardial perfusion SPECT: implications of appropriate clinical strategies.
  J Am Coll Cardiol. 2001;27:144-152
• Zellweger MJ, Pfisterer ME
  Silent Coronary Artery Disease in Patients with Diabetes Mellitus.
  Swiss Med Wkly 2001;131:427-432
• Zellweger MJ, Pfisterer ME.
  Diabetes mellitus und koronare Herzkrankheit - ein komplikationsträchtiges Duett.
  Therapiewoche 2001;17:342-346
• TIME Investigators: Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial.
  Lancet 2001;358:951-7.
• Zellweger MJ, Dubois EA, Lai S, Shaw LJ, Amanullah AM, Lewin HC, Friedman J, Kang X, Germano G, Berman DS.
  Risk Stratification in Patients with Remote Prior Myocardial Infarction. Rest/stress Myocardial Perfusion SPECT in Patients With Remote Prior Myocardial Infarction: Prognostic Value and Impact on Referral to Early Catheterization.
  Journal of Nuclear Cardiology 2002;9:23-32
• Kaiser C, Balmelli N, Pfisterer M.
  Invasive strategy in acute coronary syndromes without ST-segment elevation: when and for which patient?
  Therapeutische Umschau 2002;59: 87-91.
• Kuster GM, Buser P, Osswald S, Kaiser C, Schönenberger R, Schindler C, Amann W, Rickenbacher P, Pfisterer M; Trial of Invasive Versus Medical Therapy in the Elderly Investigators.
  Comparison of presentation, perception, and six-month outcome between women and men >75 years of age with angina pectoris.
  Am J Cardiol 2003;91:436-9.
• Zellweger MJ, Weinbacher M, Zutter AW, Jeger RV, Mueller-Brand J, Kaiser C, Buser PT, Pfisterer ME.
  Long-term outcome of patients with silent versus symptomatic ischemia 6 months after percutaneous coronary intervention and stenting.
  J Am Coll Cardiol. 2003;42:33-40
• Kaiser C, Pfisterer M.
  Management des akuten Koronarsyndroms ohne ST-Hebung (NSTEMI).
  Swiss Med Forum 2003;26:609-13.
• Kaiser C, Pfisterer M
  Perkutane koronare Intervention; Intrakoronare Bestrahlung (Brachytherapie).
  In: Buser & Zerkowski & Osterhues & Brett, & Osswald &Pfisterer, eds. Empfehlungen zur Patienteninformation, 1. Auflage. Steinkopff Verlag, Darmstadt, 2003.
• Zellweger MJ, Hachamovitch R, Kang X, Hayes SW, Friedman JW, Germano G, Pfisterer ME, Berman DS.
  Prognostic Relevance of Symptoms versus Objective Evidence of Coronary Artery Disease in Diabetic Patients
  Eur Heart J 2004;25:543-550
• Kaiser C, Kuster GM, Erne P, Amann W, Naegeli B, Osswald S, Buser P, Schläpfer H, Brett W, Zerkowski HR, Schindler C, Pfisterer M; TIME Investigators.
  Risks and benefits of optimised medical and revascularisation therapy in elderly patients with angina – on-treatment analysis of the TIME trial.
  Eur Heart J 2004;25:1036-42.
• Jeger RV, Zellweger MJ, Kaiser C, Grize L, Osswald S, Buser PT, Pfisterer ME; TIME Investigators.
  Prognostic value of stress testing in patients over 75 years of age with chronic angina.
  Chest 2004;125:1124-31.
• Claude J, Schindler C, Kuster GM, Schwenglenks M, Szucs T, Buser P, Osswald S, Kaiser C, Grädel C, Estlinbaum W, Rickenbacher P, Pfisterer M; Trial of Invasive versus Medical therapy in the Elderly (TIME) Investigators.
  Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME).
  Eur Heart J 2004;25:2195-203.
• Kaiser CA, Huegli RW, Haegeli LM, Pfisterer ME:
  Selective embolization of a pulmonary artery rupture caused by a Cournand catheter.
  Cardiovasc Interv 2004;61:317-19.
• Bonetti PO, Kaiser C, Zellweger MJ, Grize L, Erne P, Schöneneberger RA, Pfisterer ME; TIME Investigators.
  Long-term benefits and limitations of combined antianginal drug therapy in elderly patients with symptomatic chronic cornary artery disease.
  Cardiovasc Pharmacol Ther 2005;10:29-37.
• Kaufmann BA, Kaiser C, Pfisterer ME, Bonetti PO. S
  Coronary stent infection: a rare but severe complication of percutaneous coronary intervention.
  Swiss Medical Weekly 2005;135:483-7.
• Kaiser C*, Bremerich J*, Haller S, Brunner-a Rocca HP, Bongartz G, Pfisterer M, Buser P.
  Limited diagnostic yeald of non-invasive coronary angiography by 16-slice multidetector spiral computed tomography in routine patients referred for evaluation of coronary artery disease.
  Eur Heart J 2005: 26:1987-92.
  *shared first authorship
• Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger MJ, Grize L, Pfisterer ME; BASKET Investigators.
  Incremental cost-effectiveness of drug-eluting stents compared with a third-Generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial“ (BASKET).
  Lancet 2005:366:921-9.
• Kaiser C, Jeger R, Wyrsch S, Schoeb L, Kuster G, Buser P, Osswald S, Bernet F, Brett W, Grize L, Pfisterer M; TIME investigators.
  Selcetion bias of elderly patients with chronic angina referred for catheterization.
  Int J Cardiol 2006:110:80-85.
• Haller S, Kaiser C, Buser P, Bongartz G, Bremerich J
  Coronary artery imaging with contrast enhanced computed tomography: Extracardiac findings.
  Am J Roentgenol 2006. 187: 105-10.
• Bonetti PO, Zellweger MJ, Kaiser C, Pfisterer M:
  Acute coronary syndromes in special groups of patients.
  In: Betrand E, King III SB eds. Acute coronary syndromes – A handbook for clinical practice (ESC education series). Blackwell Publishing, Oxford, 2006.
• Kaiser C, Pfisterer M, Singh D.
  Paclitaxel-eluting stents appear to reduce revascularization in people with long lesions.
  Evid Based Cardiovasc Med. 2006; 10:49-51.
• Pittl U, Keller DI, Kaiser CA, Battegay M, Pfisterer ME, Linka A.
  "HAART-attack" in young female HIV-patient.
  Internist. 2006;47:939-40,942-3
• Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C, for the BASKET-LATE Investigators
  Late Clinical Events after Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents: An Observational Study of Drug-Eluting vs. Bare-Metal Stents
  JACC 2006;48:2584-91 (in press)
• Brunner-La Rocca HP, Kaiser C, Pfisterer M on behalf of the BASKET Investigators.
  Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET).
  Eur Heart J 2007;doi:10.1093/eurheartj/ehl490
• von Dahlen R, Kiencke S, Kaiser C, Rickenbacher R.
  Severe coronary artery ectasia and abdominal aortic aneurysm.
  Kardiolvaskuläre Medizin 2006; 9:438-52. 
• Kaiser CA, Bonetti PO, Pfisterer ME.
  Stellenwert der Koronarrevaskularisation bei älteren patienten mit chronischer koronarer Herzkrankheit.
  Kardiovaskuläre Medizin 2006:9:16-22
• Kaiser C.
  Die Behandlung des akuten Myokardinfarkts:eine Zeit-Angelegenheit
  Treatment of Acute Myocardial Infarction: A Matter of Time.
  Praxis 2006; 95: 1757–9
• Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbæk H, Menichelli M, Sabaté M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME,  Schömig M.
  Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents.
  N Engl J Med 356;10: 1030-39.